Utilization of tumor-informed ctDNA to de-escalate treatment or monitoring in metastatic breast cancer exceptional responders.
Janda G, Goetz M, Haddad T, Peethambaram P, Leon-Ferre R, Calkins H, Scott N, Rodriguez A, Liu M, Giridhar K. Utilization of tumor-informed ctDNA to de-escalate treatment or monitoring in metastatic breast cancer exceptional responders. Journal Of Clinical Oncology 2025, 43: e13042-e13042. DOI: 10.1200/jco.2025.43.16_suppl.e13042.Peer-Reviewed Original ResearchMetastatic breast cancerSystemic therapyCtDNA testingContinuous endocrine therapyRadiographic remissionRestaging scansEndocrine therapyExceptional respondersER+/HER2- metastatic breast cancerCohort of ptsDiscontinued systemic therapySystemic therapy optionsTreatment de-escalationBreast cancer characteristicsMedian Follow-UpDe-escalate treatmentTreating medical oncologistMetastatic breast cancer diagnosisIRB-approved protocolIncreased imaging frequencyConventional treatment paradigmsProgression of diseaseCtDNA-positiveHER2+Median duration
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply